Cargando…

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

BACKGROUND AND OBJECTIVES: Robust biomarkers that can mirror Parkinson disease (PD) are of great significance. In this study, we present a novel approach to investigate disease-associated α-synuclein (αSyn) aggregates as biomarkers of PD clinical stage. METHODS: We combined both seed amplification a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majbour, Nour, Aasly, Jan, Abdi, Ilham, Ghanem, Simona, Erskine, Daniel, van de Berg, Wilma, El-Agnaf, Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687407/ https://www.ncbi.nlm.nih.gov/pubmed/36096686 http://dx.doi.org/10.1212/WNL.0000000000201199

Ejemplares similares

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
por: Oosterveld, Linda P., et al.
Publicado: (2019)

Prion-like α-synuclein pathology in the brain of infants with Krabbe disease
por: Hatton, Christopher, et al.
Publicado: (2022)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity
por: Hmila, Issam, et al.
Publicado: (2022)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Models of α-synuclein aggregation in Parkinson’s disease
por: Giráldez-Pérez, Rosa María, et al.
Publicado: (2014)

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
por: Tatenhorst, Lars, et al.
Publicado: (2016)

CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson′s Disease
por: Oosterveld, Linda P., et al.
Publicado: (2020)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
por: Emin, Derya, et al.
Publicado: (2022)

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
por: Wang, Zerui, et al.
Publicado: (2020)

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
por: Schulz-Schaeffer, Walter J.
Publicado: (2010)

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
por: Stewart, Tessandra, et al.
Publicado: (2015)

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
por: Javed, Hayate, et al.
Publicado: (2019)

Dynamics of a model for the degradation mechanism of aggregated α-synuclein in Parkinson's disease
por: Yang, Bojie, et al.
Publicado: (2023)

Anionic Nanoplastic Contaminants Promote Parkinson’s Disease-Associated α-Synuclein Aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Decrease in Plasma Levels of α-Synuclein Is Evident in Patients with Parkinson’s Disease after Elimination of Heterophilic Antibody Interference
por: Ishii, Ryotaro, et al.
Publicado: (2015)

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
por: Karampetsou, Mantia, et al.
Publicado: (2017)

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease
por: Du, Tingting, et al.
Publicado: (2021)

New Roles of Glycosaminoglycans in α-Synuclein Aggregation in a Cellular Model of Parkinson Disease
por: Lehri-Boufala, Sonia, et al.
Publicado: (2015)

Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease
por: Basu, Sambuddha, et al.
Publicado: (2015)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
por: Recasens, Ariadna, et al.
Publicado: (2018)

Inflammatory Responses to Monomeric and Aggregated α-Synuclein in Peripheral Blood of Parkinson Disease Patients
por: Piancone, Federica, et al.
Publicado: (2021)

Mechanisms of enhanced aggregation and fibril formation of Parkinson’s disease-related variants of α-synuclein
por: Ohgita, Takashi, et al.
Publicado: (2022)

Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson’s disease
por: Hideshima, Makoto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_siafu7485lredl6fn21d786qcr